Mixed trend on the daily chart: below its 200-day average, above its 50-day · 50-day below the 200-day · SuperTrend up since Aug 26 · inside the Ichimoku cloud · RSI 51 · MACD above its signal
| 7.80 | 52-week high | +4005.26% |
| 0.2050 | Previous month high | +7.89% |
| 0.1950 | Previous week high | +2.63% |
| 0.1900 | Price now | |
| 0.1900 | R3 (classic) | −0.00% |
| 0.1900 | R2 (classic) | −0.00% |
| 0.1900 | R1 (classic) | −0.00% |
| 0.1900 | Pivot | −0.00% |
| 0.1900 | S1 (classic) | −0.00% |
| 0.1900 | S2 (classic) | −0.00% |
| 0.1900 | S3 (classic) | −0.00% |
| 0.1900 | Previous day high | −0.00% |
| 0.1900 | Previous day low | −0.00% |
| 0.0300 | Previous week low | −84.21% |
| 0.010000 | Previous month low | −94.74% |
| 0.000400 | 52-week low | −99.79% |
None of the 29 investors followed here reported a position in LYRA in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a LYRA trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Jan 5, 2026 | Palasis MariaChief Executive Officer | Sale at price 3.36 per share. | 1.7K | $5.73K |
| Jan 5, 2026 | Cavalier JasonChief Financial Officer | Sale at price 3.36 per share. | 769 | $2.59K |
| Nov 12, 2025 | Perceptive Advisors LlcBeneficial Owner of more than 10% of a Class of Security | Sale at price 3.90 - 4.31 per share. | 45.9K | $182.51K |
| Nov 9, 2025 | Perceptive Advisors LlcBeneficial Owner of more than 10% of a Class of Security | Sale at price 4.54 - 5.18 per share. | 70.4K | $344.22K |
| Jul 9, 2025 | Palasis MariaChief Executive Officer | Sale at price 8.91 per share. | 1.6K | $13.94K |
| Jul 9, 2025 | Cavalier JasonChief Financial Officer | Sale at price 8.91 per share. | 684 | $6.09K |
| Jan 7, 2025 | Palasis MariaChief Executive Officer | — | 800K | — |
| Jan 7, 2025 | Cavalier JasonChief Financial Officer | — | 420K | — |
TimeframesUp on the daily, down on the weekly and monthly, mixed on the hourly.
bouncing over the 21 EMA
over a rising 21 EMA, 21 over 50
under a falling 21 EMA, 21 under 50
under a falling 21 EMA, 21 under 50
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -42.2 | -43.3 | -51.4 | 43.6 | 5.0 | -6.1 | -31.7 | -97.9 | 200.0 | 533.3 | −93.8% | ||
| 2025 | -11.4 | 17.1 | -41.0 | -5.9 | -17.0 | 81.7 | -25.2 | 4.5 | -6.8 | -11.7 | -35.9 | -16.5 | −70.2% |
| 2024 | -13.2 | 15.6 | 18.3 | -17.0 | -93.6 | -15.6 | 17.6 | -1.1 | -20.1 | 7.0 | -24.6 | -0.4 | −96.1% |
| 2023 | -9.2 | -16.5 | -15.5 | 19.4 | 7.1 | 59.9 | -21.7 | 8.1 | 12.4 | -24.0 | 11.4 | 58.3 | +66.9% |
| 2022 | -6.2 | 19.1 | -17.5 | 40.5 | -5.3 | 5.6 | 14.9 | -10.8 | -13.5 | -6.4 | -25.2 | -10.5 | −28.0% |
| 2021 | -7.3 | 41.2 | -22.3 | -13.1 | -28.7 | 11.8 | -19.8 | 10.9 | 27.8 | -20.0 | -23.3 | -22.1 | −61.8% |
| 2020 | -28.5 | 18.2 | -2.5 | -14.5 | -4.3 | 16.1 | -8.2 | −28.2% |
No analyst coverage for this instrument.
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.